

CLINPRT-7: Intermediate Patient Population Expanded Access Protocol for MBP134 for Patients with Sudan Virus Disease (SVD)

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: Not specified

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- people of any age who have a documented positive RT-PCR for Sudan Virus Disease (SVD) in the last 10 days
- OR a documented positive RT-PCR test for SUDV more than 10 days ago but continue to have symptoms of SVD - OR acute symptoms compatible with SVD and a close contact with some who has RT-PCR confirmed SVD - OR Infants born to mothers who have a positive RT-PCR results for SUDV within 10 days of birth or with a documented positive RT-PCR test for SUDV in >10 days but with ongoing symptoms of SVD - women of who are of child-bearing age must use highly effective contraception for 90 days after receiving the medication

Exclusion Criteria:

- any medical condition that, in the opinion of the physician, would unreasonably increase risk of side effects (study staff will assess)

Conditions & Interventions

Conditions:

Infectious Diseases, Rare Diseases

Keywords:

Sudan Virus Disease, SVD

More Information

Description: The purpose of this open-label Expanded Access Protocol (EAP) is to provide access to MBP134, for treatment of Sudan Virus Disease (SVD). Patients will receive a single IV infusion of 50 mg/kg MBP134. Patients will be monitored and assessed daily through discharge for safety and the incidence of serious adverse events (SAEs), and of all adverse events (AEs) during infusions.

Study Contact: Jessica Gieseke - giese141@umn.edu

Principal Investigator: Susan Kline, MD

IRB Number: SITE00001888

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.